Viking Therapeutics soared 10.6% following Pfizer’s announcement that it would halt development of its daily weight-loss drug, danuglipron, after a trial participant experienced potential liver issues. The move has sparked speculation that Pfizer may pursue acquisitions in the GLP-1 space, where Viking is actively developing oral and injectable candidates.